Alkermes has reached an agreement to buy Avadel Pharma in a deal valued at up to $2.1 billion, claiming rights to an ...

Onsite at ESMO 2025, pharmaphorum spoke with Adrian Jubb, head of oncology and neurology clinical development at Corcept, and ...

Ipsen has reached an agreement to buy fellow French firm ImCheck Therapeutics in a deal that could be worth up to €1 billion ...

Prior to joining CMI Media Group, Freid held positions at various SaaS tech start-ups and performance focused advertising ...

Takeda has partnered with China's Innovent Biologics for a pair of late-stage cancer therapies, in a deal that includes an ...

An oversubscribed seed funding round will give Procyon the financial resources it needs to launch its first diagnostic – ...

The company ended the first half of this year with €3.1 billion ($3.6 billion) in cash reserves, and is due to report its ...

Novo Nordisk's chairman Helge Lund and several other independent board members have indicated they will step down next month, ...

However, it was the late-breaking Phase 1/2 data from the SOHO-01 study of sevabertinib (BAY 2927088) in advanced HER2-mutant ...

GSK and Spero Therapeutics' oral cabapenem, tebipenem HBr, has become the first antibiotic in the class to show efficacy in a ...

Hevia and Sousa discuss the landscape of unmet needs in metastatic castration-resistant prostate cancer, what the new data ...